Antibody Therapeutics
LightNews LightNews
banner
antibodytx.bsky.social
Antibody Therapeutics
@antibodytx.bsky.social
11 followers 4 following 27 posts
Peer-reviewed, open-access international journal published by Oxford University Press. Indexed by ESCI (IF=4.5), PubMed & Scopus (CiteScore=8.4).
Posts Replies Media Videos
antibodytx.bsky.social
New Article Alert: "RO4, a high affinity humanized antibody against the juxta membrane region of mesothelin for targeted cancer therapy" from NIH.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #Cancer #Therapy
RO4, a high affinity humanized antibody against the juxta membrane region of mesothelin for targeted cancer therapy
Statement of Significance We developed RO4, a high-affinity antibody that binds a non-shed juxtamembrane epitope, thereby avoiding interference from shed m
academic.oup.com
November 17, 2025 at 11:29 PM
antibodytx.bsky.social
New article alert: "The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity" from Shanghai Epimab Biotherapeutics.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #NK #Engager
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity
Statement of Significance Current NK cell engagers (NKCE) show limited clinical efficacy. We developed a novel tetravalent NKCE platform incorporating a re
academic.oup.com
November 3, 2025 at 11:15 PM
antibodytx.bsky.social
New article alert: "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design" from Fudan University.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #mAbs #Bispecific
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design
AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att
academic.oup.com
October 29, 2025 at 12:23 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights "Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA".
academic.oup.com/abt/article/...
#mAbs #Ab
Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA
Statement of Significance: The pharmacokinetic (PK) journey of Efineptakin alfa, a long-acting recombinant human interleukin-7, was explored through the co
academic.oup.com
October 27, 2025 at 10:26 PM
Reposted by Antibody Therapeutics
stonedhshi.bsky.social
A new paper just reached "corrected proof" stage on our journal @antibodytx.bsky.social titled "Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design".

doi.org/10.1093/abt/...

#Antibody #SingleDomainAntibody #Bispecific #OpenAccess
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design
AbstractBackground. As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing att
doi.org
October 24, 2025 at 4:43 AM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights "Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research" from Massachusetts General Hospital and Harvard Medical School.
academic.oup.com/abt/article/...
#Antibody #mAb
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research
Statement of Significance: Photoimmunotherapy (PIT) is a tumor-targeted therapy with minimal off-target effects. Recent advances in technology have expande
academic.oup.com
October 18, 2025 at 12:50 PM
antibodytx.bsky.social
New Article Alert: "Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase".
academic.oup.com/abt/advance-...
#Antibody #Therapeutics
Validate User
academic.oup.com
October 14, 2025 at 10:07 PM
antibodytx.bsky.social
New article alert: "CAR NK cell therapy for solid tumors: potential and challenges" contributed by Yanlin Yu and Mitchell Ho from NIH.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #CAR #Celltherapy
CAR NK cell therapy for solid tumors: potential and challenges
Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.
academic.oup.com
October 8, 2025 at 12:50 PM
antibodytx.bsky.social
Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights
"The process using a synthetic library that generates multiple diverse human single domain antibodies" contributed by Mark A Tornetta from Tavotek Biotherapeutics.
academic.oup.com/abt/article/...
#Antibody #Therapeutics
October 7, 2025 at 12:48 PM
antibodytx.bsky.social
New Publication Alert: "CAR NK Cell Therapy for Solid Tumors: Potential and Challenges" from National Cancer Institute, National Institutes of Health.
academic.oup.com/abt/advance-...
CAR NK Cell Therapy for Solid Tumors: Potential and Challenges
Statement of Significance This review highlights the promise of CAR NK cell therapy as a safer, off-the-shelf alternative to CAR-T cells for solid tumors.
academic.oup.com
September 15, 2025 at 10:42 PM
antibodytx.bsky.social
"Connexin 43 hemichannels and related diseases"contributed by Yanfeng Zhang (AlaMab Therapeutics) and Jean X Jiang (University of Texas Health Science Center).
Free access of the full article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs
September 3, 2025 at 9:11 PM
antibodytx.bsky.social
”An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy“ contributed by researchers from Terasaki Institute for Biomedical Innovation.
academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs #MHC
An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy
Statement of Significance: Current peptide-based cancer immunotherapy is challenged with the limited availability of immunogenic epitopes. To facilitate th
academic.oup.com
August 27, 2025 at 10:55 PM
antibodytx.bsky.social
🚀 Insightful Review in Antibody Therapeutics(IF=4.5): Mapping the protein protein interactome in the tumor immune microenvironment
academic.oup.com/abt/article/...
August 27, 2025 at 12:24 AM
antibodytx.bsky.social
🚀 Hot off the press!
We are excited to share the special collection:
"Antibody–Drug Conjugates in Cancer and Beyond",
published in Antibody Therapeutics (Impact Factor: 4.5).
📖 Read the full collection for free:
🔗 academic.oup.com/abt/pages/an...
#Antibody #Therapeutics #ADC
Special Collection: Antibody–Drug Conjugates in Cancer and Beyond
Antibody-drug conjugates (ADCs) are at the forefront of innovation in targeted cancer therapy, offering a highly effective strategy that combines the specificit
academic.oup.com
August 11, 2025 at 9:20 PM
antibodytx.bsky.social
New Publication Alert: "Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells" from University of Ottawa.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #VHH #Nanobody #CAR-T
Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells
AbstractBackground. Production of chimeric antigen receptor T cell (CAR-T) therapies depends on antibody reagents to label, isolate, and expand T cell prod
academic.oup.com
August 11, 2025 at 9:09 PM
antibodytx.bsky.social
New Publication Alert: "Structure and function of therapeutic antibodies approved by the US FDA in 2024" from William R Strohl.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics #FDA #mAbs
Structure and function of therapeutic antibodies approved by the US FDA in 2024
Abstract. In 2024, the FDA approved 47 new molecular entities (NMEs), including 15 therapeutic antibody-based molecules, marking the 30th anniversary of th
academic.oup.com
July 1, 2025 at 12:27 AM
antibodytx.bsky.social
Antibody Therapeutics, published by Oxford University Press, is proud to announce the award of its inaugural Impact Factor (4.5) by Clarivate Analytics in the latest Journal Citation Report (JCR)！
#Antibody #Therapeutics #ImpactFactor
June 18, 2025 at 11:32 AM
antibodytx.bsky.social
New Publication Alert: "Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors" from Chinese Academy of Sciences.
Free Access of Full text article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #ADC #mAbs
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
Statement of significance Many ADCs have unacceptable toxic effects, slowing their development progress. We describe the effects of ADC molecule structures
academic.oup.com
June 17, 2025 at 10:14 PM
antibodytx.bsky.social
New Publication Alert: "A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade" contributed from Mashhad University of Medical Sciences.
Free access of the full text article through academic.oup.com/abt/article/...
#Antibody #Therapeutics
A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade
Statement of Significance: The dose-dependent therapeutic effects of antibody have been reported in the treatment of some infections include: oral, skin, g
academic.oup.com
June 16, 2025 at 10:54 PM
antibodytx.bsky.social
New Publication Alert: "Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development" from WuXi XDC.
academic.oup.com/abt/article/...
#Antibody #Therapeutics #ADC #Formulation
Fundamental properties and principal areas of focus in antibody–drug conjugates formulation development
Statement of Significance: This article comprehensively reviews and summarizes the formulations of commercial antibody–drug conjugates (ADCs) for the first
academic.oup.com
June 13, 2025 at 2:12 PM
antibodytx.bsky.social
New Publication Alert: "Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality" from Food and Drug Administration.
Free access to full text article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs #Bioassay
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality
Statement of Significance: FcγR polymorphisms influence therapeutic antibody efficacy by altering receptor expression and immune responses. This review hig
academic.oup.com
June 11, 2025 at 12:09 AM
antibodytx.bsky.social
New Publication Alert: "Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo" from Navrogen.
academic.oup.com/abt/advance-...
#Antibody #Therapeutics
Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo
Statement of Significance: Multiple recent studies have highlighted the immunosuppressive impact of MUC16/CA125 on antibodies immune effector function incl
academic.oup.com
June 9, 2025 at 11:38 PM
antibodytx.bsky.social
New Publication Alert: "A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy" from Convalife Pharmaceuticals.
Free access of full text article through:https://academic.oup.com/abt/advance-article/doi/10.1093/abt/tbaf012/8140624
#Antibody #mAbs
June 4, 2025 at 11:22 AM
antibodytx.bsky.social
New CiteScore Release: Antibody Therapeutics, published by Oxford University Press, is thrilled to announce that the newest CiteScore 2024 is 8.4. Thanks all the support from our readers, reviewers, editors, and editorial board members!
June 3, 2025 at 10:31 PM
antibodytx.bsky.social
New Publication Alert: “Matching placebo development for injectable biologics—a practical tutorial” contributed by Yunsong Li from WuXi Biologics.
Free access to the article through academic.oup.com/abt/advance-...
#Antibody #Therapeutics #mAbs
Matching placebo development for injectable biologics—a practical tutorial
AbstractBackground. In drug development, placebo-controlled trials are vital for assessing treatment efficacy. Developing a suitable placebo for injectable
academic.oup.com
June 3, 2025 at 11:14 AM